Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument

Annals of Oncology

Volumn 11, Issue 3, 2000, Pages 281-288

  Trope C ^a   Kaern, J ^a   Hogberg, T ^d   Abeler, V ^a   Hagen, B ^b   Kristensen, G ^a   Onsrud, M ^b   Pettersen, E ^a   Rosenberg, P ^d   Sandvei, R ^c   Sundfor, K ^a   Vergote, I ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d NONE

Author keywords

Adjuvant chemotherapy; DNA ploidy; Early ovarian cancer; Intergroup prospective trials

Indexed keywords

CARBOPLATIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; POLYPLOIDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLOIDIES; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0033996328     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008399414923     Document Type: Article

References (53)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1995; 6: 891-3.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 4: 594-606.
3. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 1: 7-26.
4. Pettersson, F. Annual Report on the Results of Treatment in Gynaecological Cancer. Vol 21. Statements of Results obtained in patients, 1982-1986. inclusive 3-and 5-year survival up to 1990. Int J Gynecol Obstet 1991; 238-55.
5. Ozols R, Rubin SC, Thomas G et al. Epithelial ovarian cancer. In Hoskins W, Perez C, Young RC (eds): Principle and Practice of Gynecologic Oncology, second edn. Philadelphia, Pennsylvania: Lippincott-Raven 1996; 919-86.
6. Dembo AJ, Davy M, Stenwig AE et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-73.
7. Finn CB, Luesley DM, Buxton EJ et al. Is stage 1 epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol 1992; 99: 54-8.
8. Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7.
9. Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol 1983; 15: 370-80.
10. Guthrie D, Davy ML, Philips PR. A study of 656 patients with 'early' ovarian cancer. Gynecol Oncol 1984; 17: 363-9.
11. Malkasian-GD J, Melton LJ, O'Brien PC et al. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984; 149: 274-84.
12. Gadducci A, Sartori E, Maggino T et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: An Italian multicenter study. Int J Gynecol Cancer 1997; 7: 445-50.
13. Ahmed FY, Wiltshaw E, A'Hern RP et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 2968-75.
14. Baak JP, Lindeman J, Overdiep SH et al. Disagreement of histopathological diagnosis of different pathologists in ovarian tumors with some theoretical considerations. Eur J Obstet Gynecol Reprod Biol 1982; 13: 51-5.
15. Iversen OE, Skaarland E. Ploidy assessment of benign and malignant ovarian tumors by flow cytometry. A clinicopathologic study. Cancer 1987; 60: 82-7.
16. Fox H. Clinical value of new technique of gynecologic tumor assessment. Int J Gynecol Cancer 1999; 7 (Suppl 5): 337-49.
17. Vergote IB, Kaern J, Abeler VM et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993; 169: 40-7.
18. 32P). Ann Oncol 1995; 6: 887-93.
19. Young RC. Management of early ovarian cancer. Semin Oncol 1998; 25: 335-9.
20. Young RC, Brady M, Nieberg RM et al. Randomized Clinical Trial of Adjuvant Treatment of Women with Early (FIGO I-IIa high risk) Ovarian Cancer GOG 95. Proc Am Soc Clin Oncol 1999; 367.
21. Colombo N, Chiari S, Maggioni A et al. Controversial issues in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy. Gynecol Oncol 1994; 55: 541-7.
22. 32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995; 6: 887-93.
23. Trope C, Kaern J, Vergote I et al. Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group (NOCOVA) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997; 352 (Abstr 1260).
24. ten Bokkel-Huinink WW, van der Burg ME, van Oosterom AT et al. Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev 1988; 15 (Suppl B) :9-15.
25. Advanced Ovarian Cancer Trialist Group. Chemotherapy advanced ovarian cancer: An overview of randomized trials. BMJ 1991; 303: 884-93.
26. Russell P, Bannatyne P. Surgical Pathology of the Ovaries. Edinburgh: Churchill Livingstone 1989.
27. Hedley DW, Friedlander ML, Taylor IW et al. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-5.
28. Kaern J, Trope C, Kjorstad KE et al. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 1990; 38: 452-7.
29. Hiddemann W, Schumann J, Andreef M et al. Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet 1984; 13: 181-3.
30. Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
31. Cox, DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34: 187-209.
32. NIH Consensus Conference. Ovarian cancer screening, treatment, follow-up. JAMA 1995; 6: 491-7.
33. Monga M, Carmichael J, Shelley W. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinom after comprehensive surgical staging. Gynecol Oncol 1973; 43: 222-6.
34. Colombo N, Maggioni A, Bocciolone L et al. Multimodality therapy of early-stage (FIGO I-II) ovarian cancer: Review of surgical management and postoperative adjuvant treatment. Int J Gynecol Cancer 1996; 6: S113-7.
35. Hreshchyshyn MM, Park RC, Blessing JA et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 1980; 138: 139-45.
36. Vermorken JB. Clinical trials in patients with epithelial ovarian cancer: Past, present and future. Eur J Surg Oncol 1996; 22: 455-66.
37. Early Breast Cancer Trialist' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319: 1681-92.
38. Vergote I, Fyles A, Bertelsen K et al. Analysis of prognostic factor in 1287 patients with FIGO stage I invasive ovarian carcinomas. Proc ASCO 1998; 17: 360 (1389a).
39. Friedlander ML, Hedley DW, Taylor IW et al. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 1984; 44: 397-400.
40. Friedlander ML, Hedley DW, Swanson C et al. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988; 6: 282-90.
41. Kallioniemi OP, Punnonen R, Mattila J et al. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988; 61: 334-9.
42. Klemi PJ, Joensuu H, Maenpaa J et al. Influence of cellular DNA content on survival in ovarian carcinoma. Obstet Gynecol 1989; 74: 200-4.
43. Haapasalo H, Atkin NB, Collan Y et al. Tumour ploidy, morphometry, histological grading and clinical features in ovarian carcinoma: Mutual relations. Anal Cell Pathol 1991; 3: 261-71.
44. Scheueler JA, Trimbos JB, Herman J et al. The yield of surgical staging in presumed early stage ovarian cancer: Benefits or doubts? Int J Gynecol Cancer 1998; 8: 95-102.
45. Sevelda P, Dittrich C, Salzer H. Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol 1989; 35: 321-2.
46. de Sainz IC, Goff BA, Fuller AFJ et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 1-7.
47. Nasu K, Hirota Y, Kawano Y et al. Characterization of intra-operative rupture of epithelial ovarian cancer at early stage. Nippon Sanka Fujinka Gakkai Zasshi 1995; 907-10.
48. Sjovall K, Nilsson B, Einhorn. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int J Gynecol Cancer 1993; 4: 333-6.
49. Young R. Initial therapy for early ovarian carcinoma. Cancer 1987; 60: 2042-9.
50. Zanetta G. The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998; 9: 1097-101.
51. di Re F, Baiocchi G, Fontanelli R et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastases. Gynecol Oncol 1992; 62: 350-60.
52. Petru E, Lahousen M, Tamussino K et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994; 170: 656-62.
53. Pickel H. The spread of ovarian cancer. Baillieres Clin Obstet Gynaecol 1989; 3: 3-12.